Fig. 5From: 14,15-Dihydroxyeicosatrienoic acid, a soluble epoxide hydrolase metabolite in blood, is a predictor of anthracycline-induced cardiotoxicity – a hypothesis generating studyComparison of changes in 14,15-DHET levels and LVEF of DOX-treated breast cancer patients. A Left ventricular ejections fraction (LVEF) measured before, after 3 months anthracycline (DOX) treatment and at 6 months after the beginning of chemotherapy for breast cancer patients. #, reduction of LVEF higher than 10% to < 55% (cardiotoxicity). B Increase of 14,15-DHET in plasma samples of breast cancer patients collected before and after 3 months of chemotherapy measured by ELISA. *p < 0.05, triplicate values obtained by ELISA for each patient after chemotherapy compared to before chemotherapy using paired T-test. C Relationship of changes in LVEF (%) and changes in 14,15-DHET levels. Correlation coefficient is presented as an r value obtained using Pearson CorrelationBack to article page